Enhance Delivery, Pharmacokinetics & Pharmacodynamics Beyond the Barriers of the Brain, & Advance the Next Generation of Administration Technologies

With knowledge of brain barrier biology, precise modelling, and shuttle technologies accelerating at a rapid rate there has never been a more pivotal time in CNS therapeutics. The historic challenges of crossing the blood-brain-barrier present a key problem on the brink of solution with the recent critical approval in Japan by JCR Pharmaceuticals.

At the 4th Brain Barriers Summit, you will join industry experts in this discursive, resolution led forum aiming to answer the question: how can we get neurological drugs to target?

Navigating through translational concerns, pharmacodynamics and pharmacokinetics, quantifying barrier penetration, this meeting seeks to improve outcome measures as more and more companies are progressing their pipeline. At this summit you will meet and network with the decision makers and lead scientists from JCR Pharmaceuticals, Sanofi, Otsuka, Vertex, Noveome, Cerebral Therapeutics and ArunA Bio; all working to pursue this increasingly attainable goal.

Expert Speakers Include:

Bo Feng

Senior Director DMPK

Vertex Pharmaceuticals

Chaitali Ghosh

Associate Professor

Cleveland Clinic Lerner Research Institute

Mansuo Hayashi

Chief Scientific Officer

Prevail Therapeutics

Sreeraj Macha

Senior Director

Sanofi

Mathias Schmidt

President & Chief Executive Officer

JCR USA

Other Events in the World CNS Series:

Reviews From the Hanson Wade CNS Community:

“Must-attend event for anyone interested in developing therapeutics for CNS disorders.” Senior Director / Head - Antibody Discovery & Protein Engineering, Alector Pharmaceuticals

"The annual BB Summit should be a requirement for all pharma BD professionals and scientists in CNS." Chief Executive Officer, Founder & Chairman, Lauren Sciences

“High quality speakers and multiple opportunities to meet the other participants. Highly informative and interactive.” President, Creative Bio-Peptides Inc.

2022 Partner: